GBT has been the subject of a number of other research reports. Wedbush set a $103.00 price target on Global Blood Therapeutics and gave the company a buy rating in a research report on Friday, June 28th. HC Wainwright reissued a buy rating on shares of Global Blood Therapeutics in a report on Tuesday, June 25th. Oppenheimer raised their price objective on Global Blood Therapeutics from $82.00 to $89.00 and gave the company an outperform rating in a report on Thursday, May 9th. Cantor Fitzgerald set a $110.00 price objective on Global Blood Therapeutics and gave the company a buy rating in a report on Friday, June 14th. Finally, Goldman Sachs Group reissued a neutral rating and set a $75.00 price objective on shares of Global Blood Therapeutics in a report on Wednesday, May 29th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of Buy and a consensus target price of $87.46.
Shares of GBT opened at $49.90 on Friday. The company has a quick ratio of 14.51, a current ratio of 14.51 and a debt-to-equity ratio of 0.04. The firm’s 50-day simple moving average is $56.19. Global Blood Therapeutics has a 12-month low of $30.15 and a 12-month high of $64.94.
Several hedge funds and other institutional investors have recently made changes to their positions in GBT. Taylor Wealth Management Partners increased its stake in Global Blood Therapeutics by 0.5% in the 2nd quarter. Taylor Wealth Management Partners now owns 44,801 shares of the company’s stock worth $2,357,000 after purchasing an additional 217 shares during the period. State Board of Administration of Florida Retirement System increased its stake in Global Blood Therapeutics by 1.2% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 25,279 shares of the company’s stock worth $1,338,000 after purchasing an additional 310 shares during the period. BNP Paribas Arbitrage SA increased its stake in Global Blood Therapeutics by 3.7% in the 1st quarter. BNP Paribas Arbitrage SA now owns 12,522 shares of the company’s stock worth $663,000 after purchasing an additional 447 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Global Blood Therapeutics by 17.3% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,265 shares of the company’s stock worth $172,000 after purchasing an additional 482 shares during the period. Finally, Steward Partners Investment Advisory LLC purchased a new position in Global Blood Therapeutics in the 2nd quarter worth approximately $27,000.
Global Blood Therapeutics Company Profile
Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.
See Also: How Do Mutual Funds Work?
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.